Recommendations for the management of herpes zoster

Robert H. Dworkin, Robert W. Johnson, Judith Breuer, John W. Gnann, Myron J. Levin, Miroslav Backonja, Robert F. Betts, Anne A. Gershon, Maija L. Haanpää, Michael W. McKendrick, Turo J. Nurmikko, Anne Louise Oaklander, Michael N. Oxman, Deborah Pavan-Langston, Karin L. Petersen, Michael C. Rowbotham, Kenneth E. Schmader, Brett R. Stacey, Stephen K. Tyring, Albert J.M. Van WijckMark S. Wallace, Sawko W. Wassilew, Richard J. Whitley

Research output: Contribution to journalReview articlepeer-review

568 Scopus citations


The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact on quality of life, and costs of treatment. Systematic literature reviews, published randomized clinical trials, existing guidelines, and the authors' clinical and research experience relevant to the management of patients with HZ were reviewed at a consensus meeting. The results of controlled trials and the clinical experience of the authors support the use of acyclovir, brivudin (where available), famciclovir, and valacyclovir as first-line antiviral therapy for the treatment of patients with HZ. Specific recommendations for the use of these medications are provided. In addition, suggestions are made for treatments that, when used in combination with antiviral therapy, may further reduce pain and other complications of HZ.

Original languageEnglish (US)
Pages (from-to)S1-S26
JournalClinical Infectious Diseases
Issue numberSUPPL. 1
StatePublished - Jan 1 2007

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Recommendations for the management of herpes zoster'. Together they form a unique fingerprint.

Cite this